{
    "clinical_study": {
        "@rank": "52094", 
        "arm_group": {
            "arm_group_label": "Advanced Cancer Patients", 
            "description": "Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear."
        }, 
        "biospec_descr": {
            "textblock": "Tumor Biopsy Whole Blood Serum Buccal Smear Plasma Formalin Fixed Paraffin Embedded (FFPE)\n      Tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing"
        }, 
        "brief_title": "Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. A histologically or cytologically confirmed diagnosis of cancer\n\n          2. Patients with any malignancy.\n\n          3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained\n             specialists in interventional radiology) and Patients are medically fit to undergo a\n             tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a\n             tumor suitable for biopsy but have another tissue available for molecular evaluation.\n\n             OR Patients are undergoing standard of care surgeries or procedures where fresh\n             specimens will be first used for routine pathologic assessment and only then will\n             leftover tissue be used for research purposes.\n\n          4. Procedure-specific signed informed consent prior to initiation of any study-related\n             procedures.\n\n          5. Women and minorities are included in this protocol.\n\n          6. Patients with multiple malignancies remain eligible.\n\n          7. Patients with an inherited cancer syndrome or a medical history suggestive of an\n             inherited cancer syndrome remain eligible.\n\n        Exclusion Criteria:\n\n          1. It is the enrolling study physicians discretion to decide if a patient is not fit\n             enough to undergo tissue biopsy.\n\n          2. Patients who are incarcerated are not eligible to participate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with advanced or refractory cancer"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090530", 
            "org_study_id": "OSU-13053"
        }, 
        "intervention": {
            "arm_group_label": "Advanced Cancer Patients", 
            "description": "Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.", 
            "intervention_name": "Biospecimen collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cancer Genomics", 
            "Tumor Sequencing"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "The Jamesline", 
            "url": "http://cancer.osu.edu"
        }, 
        "location": {
            "contact": {
                "email": "Sameek.Roychowdhury@osumc.edu", 
                "last_name": "Sameek Roychowdhury, MD, PhD", 
                "phone": "614-685-5842"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Ohio State University Wexner Medical Center"
            }, 
            "investigator": {
                "last_name": "Sameek Roychowdhury, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing", 
        "overall_contact": {
            "email": "Jamesline@osumc.edu", 
            "last_name": "Ohio State University Comprehensive Cancer Center", 
            "phone": "1-800-293-5066"
        }, 
        "overall_contact_backup": {
            "email": "Sameek.Roychowdhury@osumc.edu", 
            "last_name": "Sameek Roychowdhury, MD, PhD", 
            "phone": "614-685-5842"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University Wexner Medical Center", 
            "last_name": "Sameek Roychowdhury, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Impact on clinical care", 
            "measure": "Number of participants receiving new therapy based on study findings", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090530"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ohio State University Comprehensive Cancer Center", 
            "investigator_full_name": "Sameek Roychowdhury", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Determine average number of days for return of results", 
            "measure": "Average number of days to return results", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "source": "Ohio State University Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ohio State University Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}